In Vivo Efficacy of WCK 5222 (Cefepime-Zidebactam) against Multidrug-Resistant Pseudomonas aeruginosa in the Neutropenic Murine Thigh Infection Model

Marguerite L. Monogue, Jennifer Tabor-Rennie, Kamilia Abdelraouf, David P. Nicolau

Research output: Contribution to journalArticlepeer-review

10 Scopus citations

Abstract

We describe the in vivo efficacy of human-simulated WCK 5222 (cefepime-zidebactam) exposure against multidrug-resistant Pseudomonas aeruginosa (meropenem MICs 8 to 256 g/ml) in a neutropenic murine thigh infection model. WCK 5222 MICs ranged from 4 to 32 g/ml. Substantial in vivo WCK 5222 activity was observed against all isolates, further enhancing the efficacy of zidebactam alone in 11/16 isolates (WCK 5222 mean reduction, –1.62 0.58 log10 CFU/thigh), and a lack of activity was observed with cefepime monotherapy.

Original languageEnglish (US)
Article numbere00233-19
JournalAntimicrobial agents and chemotherapy
Volume63
Issue number7
DOIs
StatePublished - 2019

Keywords

  • Human simulated
  • Pharmacodynamics
  • Pharmacokinetics

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'In Vivo Efficacy of WCK 5222 (Cefepime-Zidebactam) against Multidrug-Resistant Pseudomonas aeruginosa in the Neutropenic Murine Thigh Infection Model'. Together they form a unique fingerprint.

Cite this